Year : 2021 | Volume
: 6 | Issue : 4 | Page : 134--141
Disease comorbidities associated with chemical intolerance
Raymond F Palmer, Tatjana Walker, Roger B Perales, Rodolfo Rincon, Carlos Roberto Jaén, Claudia S Miller
Department of Family and Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Background: Chemical intolerance (CI) is characterized by multisystem symptoms initiated by a one-time high-dose or a persistent low-dose exposure to environmental toxicants. Prior studies have investigated symptom clusters rather than defined comorbid disease clusters. We use a latent class modeling approach to determine the number and type of comorbid disease clusters associated with CI.
Methods: Two hundred respondents with and without CI were recruited to complete the Quick Environmental Exposure and Sensitivity Inventory (QEESI), and a 17-item comorbid disease checklist. A logistic regression model was used to predict the odds of comorbid disease conditions between groups. A latent class analysis was used to inspect the pattern of dichotomous item responses from the 17 comorbid diseases.
Results: Those with the highest QEESI scores had significantly greater probability of each comorbid disease compared to the lowest scoring individuals (P < 0.0001). Three latent class disease clusters were found. Class 1 (17% of the sample) was characterized by a cluster consisting of irritable bowel syndrome (IBS), arthritis, depression, anxiety, fibromyalgia, and chronic fatigue. The second class (53% of the sample) was characterized by a low probability of any of the co-morbid diseases. The third class (30% of the sample) was characterized only by allergy.
Discussion: We have demonstrated that several salient comorbid diseases form a unique statistical cluster among a subset of individuals with CI. Understanding these disease clusters may help physicians and other health care workers to gain a better understanding of individuals with CI. As such, assessing their patients for CI may help identify the salient initiators and triggers of their CI symptoms—therefore guide potential treatment efforts.
Raymond F Palmer
7703 Floyd Curl Drive, San Antonio, TX
|How to cite this article:|
Palmer RF, Walker T, Perales RB, Rincon R, Jaén CR, Miller CS. Disease comorbidities associated with chemical intolerance.Environ Dis 2021;6:134-141
|How to cite this URL:|
Palmer RF, Walker T, Perales RB, Rincon R, Jaén CR, Miller CS. Disease comorbidities associated with chemical intolerance. Environ Dis [serial online] 2021 [cited 2022 Jan 20 ];6:134-141
Available from: http://www.environmentmed.org/article.asp?issn=2468-5690;year=2021;volume=6;issue=4;spage=134;epage=141;aulast=Palmer;type=0